ACELYRIN

ACELYRIN, Inc. (Nasdaq: SLRN) was a late-stage clinical biopharmaceutical company headquartered in Agoura Hills, California, focused on accelerating the development and commercialization of medicines in immunology. Its lead candidates were izokibep, an anti-IL-17A small protein therapeutic, and lonigutamab, a humanized IgG1 monoclonal antibody against IGF-1R. It completed a $540M IPO in May 2023, and on May 21, 2025 it merged with a subsidiary of Alumis, Inc. and survives as a wholly owned Alumis subsidiary. Its corporate domain acelyrin.com now 301-redirects to alumis.com. The company is a drug developer, not a software vendor: it published no developer program, public API, SDK, webhook surface, or machine-readable specification, and no GitHub organization exists under the ACELYRIN name.

ACELYRIN is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Biotechnology, Pharmaceuticals, and Immunology.

🌐 Visit website 📡 Profile data on GitHub

3.4/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-11-06 · rubric v0.27.0 · Show this score on your site →

0 APIs

Company Biopharmaceutical Biotechnology Pharmaceuticals Immunology Clinical Trials Healthcare Acquired

Kin Score

Kin Score How this is scored →
scored 2026-11-06 · rubric v0.27.0

Composite quality — 3.4/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 3.8 / 9

Regulatory Posture 0.7 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Delegated User Identity 0 / 6

Protected Resource Metadata 0 / 5

Registration Without a Human 0 / 6

Agentic Commerce Well-Known Document 0 / 5

Pagination 5 / 5

Distinct Operations 3 / 3

MCP Tool Quality 6 / 6

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero: never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and several others — scorable at all.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Show this score on your site.

It updates itself when the score changes. Paste this where you link to your API docs:

<a href="https://apis.io/providers/acelyrin/"><img src="https://apis.io/badge/acelyrin/card.svg" alt="ACELYRIN on APIs.io — Kin Score by API Evangelist"></a>

Other styles, a README pill and a shields.io endpoint are on the badge page.

Raise your score.

Agent readiness — checks not met, largest first (exact, from this profile):

Machine-Readable Contract +18 pts — api_specs includes an OpenAPI document
MCP Server +12 pts — deployment.mode + probe verdict on the mcp/ manifest, not the pointer; an unprobed slug falls back to authorship
Agentic Access Contract +10 pts — agentic_access artifact present (x-agentic-access), graded by author
Machine-Readable Auth +10 pts — a served openid-configuration/oauth-authorization-server carrying `issuer` (served), else the securitySchemes class in the provider OpenAPIs — bound (mutualTLS, DPoP, Signature) > negotiable (oauth2 authorizationCode/clientCredentials, openIdConnect) > bearer (http bearer, apiKey)
Idempotency +9 pts — OpenAPI mutating operations declare an idempotency key — a header, a request-body property, or a named de-duplication token whose own description says so (verified); else common[].type matches /idempoten/i (documented)
Stable Error Semantics +8 pts — OpenAPI $refs a shared error schema across 4xx/5xx responses (verified), else common[].type includes ErrorCatalog / ErrorCodes / DeclineCodes

13 more unmet checks in the Agent Readiness table above.

Kin Score — facets with the most composite points still available (weight × headroom):

Contract Quality scores 0.0 — up to +25.0 composite points
Developer Ergonomics scores 0.0 — up to +20.0 composite points
Access Clarity scores 0.0 — up to +20.0 composite points

Each check links to what satisfies it. Publish the artifact, or tell us where it already lives, and the score moves on the next scoring run.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from the provider profile at artifacts.apis.io/acelyrin/apis.yml: open an issue on github.com/api-evangelist/acelyrin to ask a question or point us at an artifact you publish. Submit an artifact on GitHub — free → Manage your own listing — the Influence plan, $499/mo →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Acelyrin Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 1

The organization behind the API

Website

Website

Source (apis.yml)

aid: acelyrin
name: ACELYRIN
description: 'ACELYRIN, Inc. (Nasdaq: SLRN) was a late-stage clinical biopharmaceutical company headquartered in Agoura Hills,
  California, focused on accelerating the development and commercialization of medicines in immunology. Its lead candidates
  were izokibep, an anti-IL-17A small protein therapeutic, and lonigutamab, a humanized IgG1 monoclonal antibody against IGF-1R.
  It completed a $540M IPO in May 2023, and on May 21, 2025 it merged with a subsidiary of Alumis, Inc. and survives as a
  wholly owned Alumis subsidiary. Its corporate domain acelyrin.com now 301-redirects to alumis.com. The company is a drug
  developer, not a software vendor: it published no developer program, public API, SDK, webhook surface, or machine-readable
  specification, and no GitHub organization exists under the ACELYRIN name.'
url: https://raw.githubusercontent.com/api-evangelist/acelyrin/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
x-parent-company: alumis
x-secondary-market-listing: https://forgeglobal.com/acelyrin_stock/
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  probe_state: none
  source:
  - security
  generated: '2026-11-06'
  method: derived
specificationVersion: '0.20'
created: '2026-09-06'
modified: '2026-09-06'
tags:
- Company
- Biopharmaceutical
- Biotechnology
- Pharmaceuticals
- Immunology
- Clinical Trials
- Healthcare
- Acquired
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/acelyrin-domain-security.yml
- type: Website
  url: https://acelyrin.com/
x-enrichment:
  date: '2026-09-06'
  status: minimal
  artifacts_added: 2
  pass: local-v3
x-coverage:
  state: none
  reason: defunct
  detail: ACELYRIN was absorbed into Alumis, Inc. on 2025-05-21 as a wholly owned subsidiary and its corporate domain acelyrin.com
    now 301-redirects to www.alumis.com, so the only surviving surface belongs to the acquirer; the company was a clinical-stage
    drug developer that never published a developer portal, API, or GitHub organization.
  evidence:
  - url: https://acelyrin.com/
    status: 301
  - url: https://www.alumis.com/
    status: 200
  - url: https://acelyrin.com/.well-known/api-catalog
    status: 404
  - url: https://acelyrin.com/openapi.json
    status: 404
  - url: https://api.github.com/orgs/acelyrin
    status: 404
  checked: '2026-09-06'
x-legal-name: ACELYRIN, Inc.

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this

find_providersBrowse and filter every provider in the catalog.
get_provider_artifactsEvery artifact this provider publishes, grouped by type.
get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
get_provider_ratingPRO — composite, band, trend and facet scores.
apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
resolveTurn a domain, URL or GitHub org into the provider it belongs to.
find_cohortsEvery scored population of providers in the catalog.

All 92 tools →

Call it yourself

curl for this page

This provider

curl "https://apis.io/api/v1/providers/acelyrin"

All providers

curl "https://apis.io/api/v1/providers?limit=25"

Every operation they expose

curl "https://apis.io/api/v1/providers/acelyrin/operations?limit=25"

How their score was established

curl "https://apis.io/api/v1/providers/acelyrin/evidence"

Calls without X-API-Key need no key. Calls with it need a paid plan — get a key.

Get an API key

Free tier, no form to fill in. Signing in shares your email address with us — we store it to create your key and to recognise you if you sign in with another provider. See our Privacy Policy and Terms.

GitHub Google LinkedIn

A second provider on the same verified email joins the account you already have.